Consistent with our findings, the association of sPD-L1 with disease advancement parameters has been identified in various other tumors: in aggressive bladder cancer (55), advanced (ccRCC) (12), and gastric cancer (35). Here, SPDL1 is linked to urinary bladder cancer.